Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Therapeutic potential of targeting lipid aldehydes and lipoxidation end-products in the treatment of ocular disease.

Authors
  • McDowell, Rosemary E
  • McGeown, J Graham
  • Stitt, Alan W
  • Curtis, Tim M
Type
Published Article
Journal
Future Medicinal Chemistry
Publisher
"Future Science, LTD"
Publication Date
Feb 01, 2013
Volume
5
Issue
2
Pages
189–211
Identifiers
DOI: 10.4155/fmc.12.202
PMID: 23360143
Source
Medline
License
Unknown

Abstract

Lipoxidation reactions and the subsequent accumulation of advanced lipoxidation end products (ALEs) have been implicated in the pathogenesis of many of the leading causes of visual impairment. Here, we begin by outlining some of the major lipid aldehydes produced through lipoxidation reactions, the ALEs formed upon their reaction with proteins, and the endogenous aldehyde metabolizing enzymes involved in protecting cells against lipoxidation mediated damage. Discussions are subsequently focused on the clinical and experimental evidence supporting the contribution of lipid aldehydes and ALEs in the development of ocular diseases. From these discussions, it is clear that inhibition of lipoxidation reactions and ALE formation could represent a new therapeutic avenue for the treatment of a broad range of ocular disorders. Current and emerging pharmacological strategies to prevent or neutralize the effects of lipid aldehydes and ALEs are therefore considered, with particular emphasis on the potential of these drugs for treatment of diseases of the eye.

Report this publication

Statistics

Seen <100 times